Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBIT Margin: 2022-2025

Historic EBIT Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -158.56%.

  • bioAffinity Technologies' EBIT Margin fell 7458.00% to -158.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -153.20%, marking a year-over-year decrease of 6407.00%. This contributed to the annual value of -95.64% for FY2024, which is 21920.00% up from last year.
  • bioAffinity Technologies' EBIT Margin amounted to -158.56% in Q3 2025, which was up 19.98% from -198.16% recorded in Q2 2025.
  • bioAffinity Technologies' EBIT Margin's 5-year high stood at 59.61% during Q2 2022, with a 5-year trough of -169,160.69% in Q1 2023.
  • Its 3-year average for EBIT Margin is -16,357.17%, with a median of -141.73% in 2025.
  • Per our database at Business Quant, bioAffinity Technologies' EBIT Margin crashed by 906,939bps in 2023 and then soared by 16,907,986bps in 2024.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' EBIT Margin stood at -69,213.17% in 2022, then soared by 6,910,734bps to -105.83% in 2023, then tumbled by 2,764bps to -133.47% in 2024, then crashed by 7,458bps to -158.56% in 2025.
  • Its EBIT Margin was -158.56% in Q3 2025, compared to -198.16% in Q2 2025 and -141.73% in Q1 2025.